Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

The accuracy of non-invasive blood and stool-based tests for colorectal cancer is improving, but experts say it’s too soon to drop colonoscopies altogether.

Complementary value of a digital pathology biomarker to post-surgery circulating tumor DNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy. This is an ASCO ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named ...

Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic profiling in patients with advanced or metastatic solid tumors. This is an ASCO Meeting Abstract from ...

Think of them as medical detectives, helping doctors detect issues at the genomic level before they become life-threatening emergencies.

The discovery began, as many breakthroughs do, with an observation that didn’t quite make sense. In 1948, two French researchers, Paul Mandel and Pierre Métais, published a little-noticed paper in a ...

Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...